A Mitchell Phelps, PhD
College of Pharmacy
>Leukemia, Lymphocytic, Chronic, B-Cell ● Cancer ● Tumor Lysis Syndrome ● Leukemia, Myeloid, Acute ● Precursor Cell Lymphoblastic Leukemia-Lymphoma ● Lymphoma, Non-Hodgkin ● Biliary Tract Cancer ● Lymphoma, Mantle-Cell
A. Mitchell Phelps, PhD, is a member of the Leukemia Research Program at the OSUCCC – James, where he uses his expertise in analytical methodologies and data modeling to study novel anticancer agents.His work involves the development of novel anticancer agents and immunotherapies. Dr. Phelps is also interested in understanding factors that influence the absorption, distribution, metabolism and excretion of these agents and how those factors impact activity in preclinical animal models and clinical outcomes in patients. One of his recent studies indicated how variability in melphalan drug exposure and the timing of co-administered granulocyte-colony stimulating factor influences the duration of severe neutropenia in myeloma patients undergoing stem cell transplant. Dr. Phelps has co-authored many articles in well-respected publications, including Clinical Pharmacology and Therapeutics, Journal of Clinical Oncology, Journal of Immunotoxicology and Cancer Immunology Research.